ENLV, IL0011319527

Enlivex receives Nasdaq delisting notice: what it means for Enlivex stock

Published on 10/27/2026 at 13:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nasdaq cited 30 sessions below USD 1.00 on October 26, 2026. Enlivex stock can keep trading during an appeal hearing.

Nasdaq compliance and trial timing

Nasdaq cited 30 consecutive business days below USD 1.00 in a notice dated October 26, 2026.
Enlivex's October 19 plan reduced its workforce by 60 percent and targeted Phase 2b execution.
Enlivex's scheduled reporting date is November 13, 2026.

ENLV, IL0011319527, Illustration mit AI erstellt.

Enlivex (ISIN IL0011319527) disclosed that Nasdaq cited 30 consecutive business days below the USD 1.00 minimum bid requirement in a delisting notice dated October 26, 2026. According to GlobeNewswire on October 27, 2026, the company plans to appeal the decision through an oral hearing request.

Three October steps reshaped Enlivex

On October 19, 2026, Enlivex announced a cost reduction plan that included a 60 percent workforce reduction and a focus on its Phase 2b Allocetra trial, according to Enlivex. On October 22, 2026, the company announced a 1-for-16 reverse share split, reducing issued shares from 24,511,905 to approximately 1,531,995, as reported by Markets Insider. On October 27, 2026, the Nasdaq delisting notice became the latest event, with the company saying the reverse split had taken effect and that it intended to appeal.

What does the appeal mean?

The appeal is central because a timely hearing request stays any suspension or delisting action while the Nasdaq process continues. The company also said its ordinary shares would continue trading on the Nasdaq Capital Market during the appeal, although it gave no assurance that the appeal would succeed. The 1-for-16 split is therefore both a capital-structure change and part of the effort to regain compliance.

Two dates shape the next phase

Earnings Today lists November 13, 2026, as Enlivex's scheduled reporting date. The October 19 company release also said topline six-month data from the Phase 2b trial are expected by mid-2027, giving the clinical program a longer-term milestone.

Trading status depends on Nasdaq review

For investors, the immediate issue is the interaction between Nasdaq compliance, the reverse split and the appeal process. Enlivex remains a clinical-stage biotechnology company developing Allocetra while operating a prediction markets treasury strategy.

The further course of trading is shown by the continuously updated real-time quote of Enlivex stock.